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Background.Assessmentofwhiteadiposetissuehaschangedinrecentyears,withWATnowbeingconsideredasanactiveendocrine
organ,secretingalargenumberofbioactivemediators,so-calledadipokines.Besidesotherfunctions,theseadipokinesareinvolved
in inﬂammatory response thereby exhibiting predominantly proinﬂammatory or anti-inﬂammatory properties and contribute to
insulinresistance.Methods.Comprehensivereviewoftheliteratureoftheroleofadipokinesrelevanttocriticalcaremedicineusing
PubMed search. Results. Adiponectin—the prototype of an anti-inﬂammatory and insulin-sensitizing adipokine—is diminished
in sepsis, while resistin—a protein with proinﬂammatory properties—is elevated. Plasminogen activator inhibitor-1, interleukin
(IL)-1, IL-6, IL-8, and IL-10, and tumor-necrosis-factor-alpha mediate insulin resistance and are elevated in sepsis, while retinol-
binding protein-4 concentrations are signiﬁcantly reduced in sepsis. Chemerin displays potent anti-inﬂammatory and insulin-
resistance properties, while monocyte chemotactic protein-1—increased in sepsis—contributes to macrophage inﬁltration in
adipose tissue and insulin resistance. Conclusions. The expression of adipokines in humans is altered as well in obese as in septic
patients with elevated levels of proinﬂammatory adipokines. Changes in adipokine levels in acute sepsis could contribute to
insulin resistance. Consequently, in critically ill patients, these alterations underline a possible contribution of adipokines in the
development of hyperglycemia.
1.Introduction
Severe sepsis is a syndrome characterized by systemic inﬂam-
mationandacuteorgandysfunctioninresponsetoinfection.
This inﬂammatory response is largely mediated by pro- and
anti-inﬂammatory cytokines, which are released into the
systemic circulation. While these cytokines are a prerequisite
toﬁghtinfection,theiroverzealousproductionisdeleterious.
White adipose tissue (WAT) is involved in biosynthesis of
these cytokines. WAT was traditionally considered a long-
term energy storage depot with few interesting attributes.
Due to the dramatic rise in obesity and its secondary diseases
like metabolic syndrome during the past decades, adipose
tissue is now considered to be an active endocrine organ
that releases a large number of bioactive mediators, so-called
adipokines. So far, more than 50 adipokines are known,
and their number is still rising (adipokines here deﬁned as
signaling proteinaceous factors mainly produced or released
by adipose tissue) [1].
At the cellular level, there is a substantial heterogene-
ity in WAT, especially in obese individuals—with mature
adipocytes accounting for only about half of the total cell
content. Other cells in WAT include ﬁbroblasts, endothelial
cells, preadipocytes, and in particular macrophages residing
in the stromavascular fraction of WAT [2]. By acting as
transmitters of endocrine or paracrine signals, the secreted
adipokines are involved in the inﬂammatory process and
insulin resistance. The expression of these adipokines is al-2 International Journal of Inﬂammation
Table 1: Proinﬂammatory or anti-inﬂammatory properties of
adipokines, serum level changes of adipokines in septic or obese
patients, and inﬂuence of adipokines on insulin sensitivity in
patients with sepsis or obese patients.
Adipokine Anti- Pro- Humans with Insulin
inﬂammatory eﬀect sepsis obesity sensitivity
Adiponectin + ↓↓ ↑
Chemerin + ↑↑ ↓
Resistin + ↑→→
PAI-1 + ↑↑ ↓
Visfatin + ↑↑
MCP-1 + ↑↑ ↓
TNF-α + ↑→ (?) ↓
IL-1 + ↑↑ ↓
IL-6 + ↑↑ ↓
IL-8 + ↑↑ ↓
IL-10 + ↑↑ ↑
Leptin →→ → ↑ ?
RBP 4 + ↓↑ ↓
tered in obese as well as in septic patients with elevated
levels of proinﬂammatory adipokines [3]. Therefore, obesity
is associated with the appearance of a chronic, low inﬂam-
matory state [4]. Insulin resistance is a common feature
in obesity. In analogy, changes in adipokine levels in acute
sepsis could also contribute to insulin resistance in critically
ill patients. Among the multitude of adipokines, this paper
focuses on adiponectin, leptin, resistin, visfatin, chemerin,
tumor necrosis factor-α (TNF-α), Interleukin (IL)-1, IL-
6, IL-8, IL-10, plasminogen-aktivator-inhibitor-1 (PAI-1),
monocyte chemoattractant protein-1 (MCP-1), and retinol-
binding protein-4 (RBP-4) as adipokines with particular
emphasis on their inﬂuence on severe sepsis and on sepsis-
related insulin resistance.
2. Adiponectin
Adiponectin—the prototype of anti-inﬂammatory adipok-
ines—is the most abundant adipokine produced almost
exclusively by mature adipocytes. Its blood concentration
is much higher than the concentration of other known
hormones, accounting for approximately 0.01% of the total
plasma protein [5]. Serum levels of adiponectin are dimin-
ished in obese individuals and correlate negatively with the
degree of obesity (Table 1). Due to insulin-sensitizing eﬀects
of adiponectin in humans, its plasma levels are inversely
correlated with insulin resistance in type 2 diabetes (T2D)
[6]. Besides obesity, lower adiponectin levels have also been
found in critically ill patients [3, 7]. For these patients, a
strong association between plasma cortisol and adiponectin
as well as an inverse correlation between plasma CRP and
adiponectin has been described. Furthermore, adiponectin
levels correlate negatively with severity of sepsis.
Referring to the way of action, recent studies showed
that adiponectin attenuates inﬂammation on several levels
(Figure1). It suppresses the functionof mature macrophages
and inhibits foam cell formation (lipid accumulation in
macrophages) as well as growth of macrophage precursors
[8]. In addition, adiponectin attenuates the production of
TNF-α a n dI L - 6p r o d u c t i o ni nm a c r o p h a g e s ,i n d u c e st h a t
of anti-inﬂammatory IL-10, and inhibits Toll-like receptor
family-induced signaling in mouse macrophages [9, 10].
Given the anti-inﬂammatory eﬀects of adiponectin, it is
plausible that lowered adiponectin levels may predispose to
sepsis-related proinﬂammatory complications in states of
obesity, diabetes, and insulin resistance. Further, the reduced
adiponectin levels in septic patients may support insulin
resistance in critically ill patients although it was shown,
that adiponectin levels and insulin demand were positively
correlated during sepsis [11].
3.Resistin
Besides adiponectin, resistin was reported to participate
in the inﬂammatory response [12]. Resistin was originally
discovered in mice as an adipocyte-derived hormone. It is
increased in obese mice and causes insulin resistance in
mice [13]. In contrast to mice, resistin in humans is mainly
derived from macrophages rather than from adipocytes, so
it is no surprise that proinﬂammatory resistin is elevated
in a state of systemic inﬂammation [14]. Controversy exists
on whether resistin can be considered a true adipose tissue-
derived protein. Resistin is included, since serum resistin
levels will increase with both increased adiposity and sever
inﬂammation.
Its secretion is stimulated by inﬂammatory processes,
glucocorticoids, and lipopolysaccharides (LPSs), whereas
TNF-α and β-adrenergic stimulation act as inhibitory [15].
Resistin increases transcriptional events leading to higher
expression of several proinﬂammatory cytokines including
IL-1, IL-6, IL-12, and TNF-α [16]. In a positive feedback
loop, resistin can be upregulated by interleukins, and also by
microbialantigenssuchasLPS[17].Inaccordancewiththese
reports, signiﬁcantly higher resistin levels were found in sep-
ticpatients,andresistinlevelswereassociatedwithseverityof
sepsis supporting the hypothesis that resistin predominantly
participates in systemic inﬂammatory response to infection
[3]. No relationship between resistin concentration and
insulin resistance has been found [18].
4.Leptin
The adipose-derived hormone leptin is well known for its
contribution to energy metabolism and satiety signaling in
the hypothalamus. Circulating leptin levels directly reﬂect
adipose tissue mass. Furthermore, leptin aﬀects glucose
metabolism and increases insulin sensitivity. Obese humans
are often insulin and leptin resistant [19]. The role of leptin
in sepsis and septic shock is still controversially discussed.
Earlier reports suggested that high lepin levels are associated
with increased survival in sepsis and septic shock [20, 21],
whereas several other reports fail to show a correlation
between leptin and sepsis [22]. Minor changes of leptin
serum levels in septic patients are reported with variousInternational Journal of Inﬂammation 3
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Figure 1: Primary cellular source of proinﬂammatory (red), anti-inﬂammatory (green), and neutral (yellow) adipokines.
slight increase or decrease during the course of sepsis, not
beingr elat edeithert osurvi valort ometabolicandhormonal
changes [23]. The inﬂuence of leptin on insulin resistance is
still not fully understood, whereby studies in lipodystrophic
patients and in patients with mutations of the insulin re-
ceptor have indicated that leptin therapy is associated with
a marked improvement in the metabolic state of the pa-
tients with remarkable improvements in insulin sensitivity
[24].
5. Plasminogen Activator Inhibitor-1(PAI-1)
Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of
ﬁbrinolysis produced by visceral and subcutaneous adipo-
cytes, endothelial cells, and stromal cells in visceral adipose
tissue [25].
The plasminogen activation system is part of the ﬁb-
rinolysis which is tightly regulated and protected against
dysfunction by various activators and inhibitors. PAI-1
interacts with proteolytic mediators, including urokinase
plasminogen activator. Microorganisms including bacteria
have been proven to interact with components of the
ﬁbrinolytic pathways for their own beneﬁts including dis-
seminationwithinthehostandevasionofhostinﬂammatory
immune response [26]. Studies in a rodent model suggested
that microvascular thrombosis in sepsis is associated with
inhibition of ﬁbrinolytic processes by PAI-1 [27].
PAI-1 participates in acute inﬂammatory conditions
with intrinsic proinﬂammatory properties via neutrophil
activation and subsequent release of the proinﬂammatory
cytokines IL-1 and TNF-α by neutrophils [28]. As in obesity,
PAI-1 is elevated in inﬂammatory conditions, and serum
levels correlate with the severity of sepsis [3]. Levels of PAI-1
arealsopositivelyrelatedtopooroutcome,increasedseverity
of disease, and increased levels of various cytokines, acute-
phase proteins, and coagulation parameters [29]. Elevated
PAI-1 levels seem also to have a direct causal role in insulin
resistance,sinceinsulinsensitivitywasenhancedsigniﬁcantly
inobesemicelackingPAI-1(high-fat/high-carbohydratediet
induced) [30].4 International Journal of Inﬂammation
6. InterleukinsandTNF-α
Plasma concentrations of IL-1, IL-6, and IL-8, and TNF-
α are increased in response to inﬂammation. Macrophages
in adipose tissue are a signiﬁcant source of these cytokines,
whereby IL-6 and IL-8 are directly produced by adipocytes,
in addition [31–34]. TNF-α and IL-1 are some of the
most important mediators of inﬂammation [33]. IL-1 and
TNF-α mutually enhance each other’s production and act
synergistically. Their expression and secretion increase upon
obesity and correlate positively with the body mass index.
IL-1 and TNF-α are involved in obesity-related insulin
resistance. IL-1 can promote β-cell destruction and alter
insulin sensitivity and insulin signaling. TNF-α is known to
promote lipolysis and the secretion of free fatty acids, which
contribute to an increase in hepatic glucose production [35].
On a cellular level, TNF-α is a potent inhibitor of the insulin-
stimulatedtyrosinephosphorylationonthebeta-chainofthe
insulin receptor and insulin receptor substrate-1 [36].
IL-6 can act both as a pro- and anti-inﬂammatory
cytokines. It is known to act similarly to TNF-α,b u tc o n t r o -
versial ﬁndings also have been reported for their actions
on insulin sensitivity [37]. Acute IL-6 administration to
humans increases insulin-stimulated glucose disposal and
fatty acid oxidation in vivo. Furthermore, IL-6 stimulates the
production of anti-inﬂammatory cytokines and suppresses
TNF-α production in humans. In contrast, in adipose tissue,
IL-6 concentration is inversely related to insulin-stimulated
glucose transport in adipocytes and to insulin sensitivity
[35]. Presumably, obesity and T2D-associated persistent
systemic increases of IL-6 may trigger insulin resistance
[38]. In vitro studies showed direct decreasing eﬀects of
IL-6 and TNF-α on adiponectin mRNA levels in adipose
tissue cultures [39]. In analogy, elevated IL-1, IL-6, and
TNF-α levels in septic patients may contribute to insulin
resistance.
7. Chemerin
Chemerin is expressed in adipose tissue [40]. Initially, it
was reported as a proinﬂammatory molecule, while later-
on studies revealed the existence of an anti-inﬂammatory
chemerin cleavage product [41]. It is synthesized as an
inactive precursor (prochemerin) requiring the processing
of its C terminus for generating active chemerin—an
agonist of chemerin receptor 23 (ChemR23), a receptor
expressed on dendritic cells and macrophages. Angiotensin-
converting enzyme (ACE) may be responsible for the
activation of prochemerin [42]. Receptor-ligand binding
elicits chemotaxis of macrophages and immature, but not
mature, dendritic cells [40] .I nam o u s em o d e lo fa c u t el u n g
injury, chemerin displays potent anti-inﬂammatory prop-
erties, reducing neutrophil inﬁltration and inﬂammatory
cytokine release [43]. Chemerin plasma levels have been
shown to have a signiﬁcant association with inﬂammation.
Sincepro-andanti-inﬂammatoryresponsestoastimulus
are often simultaneous—like a two-edged sword—chemerin
was also shown to be proinﬂammatory by recruitment and
retention of macrophages at sites of inﬂammation [44].
Chemerin levels increase with BMI in humans. Higher
levels are associated with insulin resistance at the level of
lipogenesis and insulin-induced antilipolysis in adipocytes.
Chemerin also induces insulin resistance in human skele-
tal muscle cells [45]. Consequently, elevated secretion of
chemerin may be involved in the negative crosstalk between
adipose tissue and skeletal muscle contributing to the
negative relationship between inﬂammation and insulin
sensitivity.
8.Retinol BindingProtein-4(RBP-4)
Retinol binding protein-4 (RBP-4) is the principal transport
protein for retinol (vitamin A) produced by adipocytes and
appears to aﬀect insulin action. Increased serum RBP-4
levels have been reported in obesity and T2D and decrease
with improved insulin sensitivity [46]. In mice, transgenic
expression of RBP-4 caused insulin resistance, and RBP-
4 knockout mice display enhanced insulin sensitivity [46].
Oversecretion of RBP-4 may negatively aﬀect beta-cell func-
tiondirectlyorbypreventingthebindingoftransthyretin—a
β-cell stimulus—to its receptor [47]. Furthermore, RBP-4-
associated eﬀects are the increase of hepatic gluconeogenesis
by enhancing the expression of phosphoenolpyruvate car-
boxykinase in the liver and the attenuated insulin signaling
in skeletal muscle [46].
RBP-4 is associated with altered insulin resistance in
critical illness. Patients with sepsis had lower levels of RBP-
4 than did nonseptic patients. When critical illness was
sustained, RBP-4 levels returned to normal reference values.
Insulin therapy blunts the rise of RBP-4 levels [48]. In
acute critically ill patients, serum RBP-4 concentrations were
signiﬁcantly reduced and showed a strong association with
hepatic dysfunction, insulin resistance, and acute mortality,
possibly as a negative acute phase reactant [49]. RBP-4 can
induce the production of IL-6 and TNF-α in bone marrow
derived macrophages [50].
9.Visfatin
Visfatin—also known as pre-B-cell-enhancing factor (PBEF)
/nicotinamide phosphoribosyl transferase (NAMPT)—was
named for the suggestion that it would predominantly
be produced and secreted in visceral fat. However, it was
f o u n dt ob ee x p r e s s e df a i r l yw i d e l yb yv a r i o u sc e l lt y p e s
throughout the body, in particular from macrophages in
response to inﬂammatory signals rather from adipocytes
[51].PBEF/NAMPT/visfatinservesintracellularlyastherate-
limiting enzyme that catalyzes the ﬁrst step in nicotinamide
adeninedinucleotide(NAD)biosynthesisfromnicotinamide
and that regulates growth, apoptosis, and angiogenesis of
mammalian cells [52]. Extracellular PBEF/NAMPT/visfatin
is reported to exert insulin-mimetic eﬀects in cultured cells
and to decrease plasma glucose levels in mice by bind-
ing to and activating the insulin receptor. However, the
physiological relevance of visfatin remains controversial due
to conﬂicting results regarding its possible connection to
obesity, T2D, and other metabolic complications in subse-
quent studies [53].International Journal of Inﬂammation 5
Clinical and experimental studies have shown that the
expression and secretion of PBEF/NAMPT/visfatin is upreg-
ulated during inﬂammation and in response to proinﬂam-
matory cytokines. Furthermore, PBEF/NAMPT/visfatin it-
self can contribute to the inﬂammatory processes by trigger-
ing cytokine production and NF-kappaB activation [54]. It is
expressed at high levels in neutrophils harvested from septic
critically ill patients and contributes to prolonged neutrophil
survival in clinical sepsis [55]. It exerts proinﬂammatory
propertiesinactivatinghumanleukocytesandintroducesIL-
1β,T N F - α, and especially IL-6 production [56]. Biochemical
neutralization of PBEF/NAMPT/visfatin has been proven to
be eﬀective in several models of inﬂammation including
sepsis [57].
10.MCP1
Monocyte chemotactic protein-1 (MCP-1)—also known as
CCL-2 (CC-chemokine ligand 2)—produced by adipocytes
contributes to macrophage inﬁltration in adipose tissue
[58]. Chemokines are known to play an important role
in the pathogenesis of sepsis and endotoxemia. Increased
concentrations of MCP-1 have been associated with sepsis
and prediction of sepsis-related mortality [59].
Its pathophysiological role has been linked to the acti-
vated protein C pathway and its induced genes [60]. MCP-1
positivelyregulatesIL-10butnegativelycontrolsmacrophage
migrationinhibitoryfactor(MIF)inexperimentalperitoneal
sepsis, suggesting an important immunomodulatory role for
MCP-1 in controlling the balance between proinﬂammatory
and anti-inﬂammatory factors in sepsis [61]. Serum levels
of MCP-1 in septic patients are increased considerably com-
paredtoamuchlowerriseinthemorbidlyobese.Theseacute
increased serum concentrations of MCP-1 in sepsis seem
to contribute substantially to systemic insulin resistance—
irrespective of a preexisting adipose tissue inﬂammation
[62].
11. Conclusions
Adipokines reveal proinﬂammatory and/or anti-inﬂamma-
tory eﬀects. Adiponectin—the prototype of an anti-inﬂam-
matory adipokines and the most abundant adipokine—is
diminished in sepsis, while the levels of resistin—a protein
with proinﬂammatory properties—are elevated. Most other
adipokines in humans are either increased or decreased in
sepsis, and alterations are in the same directions as in obese
individuals. In obesity, chronic inﬂammation in adipose tis-
sue is thought to be important for the development of in-
sulin resistance. Hyperglycemia and insulin resistance are
also well-known features of critical illness. The ﬁnding of
altered levels of adipokines in septic patients underlines its
possible contribution in the development of hyperglycemia
and insulin resistance in these patients.
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